$29.90
At close: May 21 EDT
$30.90
1.003.34%
Pre-Market: 4:46 AM EDT
Comments
Loading...
Tonix Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:TNXP | Benzinga
Tonix Pharmaceuticals Holding Corp has a consensus price target of $28 based on the ratings of 3 analysts. The high is $70 issued by Noble Capital Markets on March 20, 2025. The low is $3 issued by Dawson James on February 28, 2024. The 3 most-recent analyst ratings were released by Noble Capital Markets, Alliance Global Partners, and Dawson James on March 20, 2025, July 22, 2024, and February 28, 2024, respectively. With an average price target of $28 between Noble Capital Markets, Alliance Global Partners, and Dawson James, there's an implied -9.39% downside for Tonix Pharmaceuticals Holding Corp from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Noble Capital Markets
Alliance Global Partners
Dawson James
1calculated from analyst ratings
Analyst Ratings for Tonix Pharmaceuticals
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/20/2025 | Buy Now | 126.54% | Noble Capital Markets | Robert LeBoyer47% | $70 → $70 | Reiterates | Outperform → Outperform | Get Alert |
| 07/22/2024 | Buy Now | -64.4% | Alliance Global Partners | James Molloy30% | $6 → $11 | Maintains | Buy | Get Alert |
| 02/28/2024 | Buy Now | -90.29% | Dawson James | Jason Kolbert42% | → $3 | Initiates | → Buy | Get Alert |
| 08/01/2023 | Buy Now | -74.11% | Alliance Global Partners | James Molloy30% | $18 → $8 | Maintains | Buy | Get Alert |
| 06/02/2023 | Buy Now | -41.75% | Alliance Global Partners | James Molloy30% | $6.5 → $18 | Maintains | Buy | Get Alert |
| 01/12/2023 | Buy Now | -78.96% | Alliance Global Partners | James Molloy30% | → $6.5 | Reiterates | → Buy | Get Alert |
FAQ
What is the target price for Tonix Pharmaceuticals (TNXP) stock?
The latest price target for Tonix Pharmaceuticals (NASDAQ:TNXP) was reported by Noble Capital Markets on March 20, 2025. The analyst firm set a price target for $70.00 expecting TNXP to rise to within 12 months (a possible 126.54% upside). 2 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Tonix Pharmaceuticals (TNXP)?
The latest analyst rating for Tonix Pharmaceuticals (NASDAQ:TNXP) was provided by Noble Capital Markets, and Tonix Pharmaceuticals reiterated their outperform rating.
When was the last upgrade for Tonix Pharmaceuticals (TNXP)?
There is no last upgrade for Tonix Pharmaceuticals
When was the last downgrade for Tonix Pharmaceuticals (TNXP)?
There is no last downgrade for Tonix Pharmaceuticals.
When is the next analyst rating going to be posted or updated for Tonix Pharmaceuticals (TNXP)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Tonix Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Tonix Pharmaceuticals was filed on March 20, 2025 so you should expect the next rating to be made available sometime around March 20, 2026.
Is the Analyst Rating Tonix Pharmaceuticals (TNXP) correct?
While ratings are subjective and will change, the latest Tonix Pharmaceuticals (TNXP) rating was a reiterated with a price target of $70.00 to $70.00. The current price Tonix Pharmaceuticals (TNXP) is trading at is $30.90, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
